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Abstract
Thyroid hormone (TH) is essential for normal development, growth and metabolism. Its effects were thought to be
principally mediated through triiodothyronine (T3), acting as a ligand for the nuclear TH receptors (TRs) a and b
residing on thyroid hormone response elements (TREs) in the promoter of TH target genes. In this classical model
of TH action, T3 binding to TRs leads to recruitment of basal transcription factors and increased transcription of TH
responsive genes.
Recently, the concept of TH action on gene expression has become more diverse and now includes nonclassical
actions of T3 and T4: T3 has been shown to activate PI3K via the TRs, which ultimately increases transcription of
certain genes, e.g. HIF-1a. Additionally, both T3 and thyroxine (T4) can bind to a membrane integrin, avb3, which
leads to activation of the PI3K and MAPK signal transduction pathways and finally also increases gene transcription,
e.g. of the FGF2 gene. Therefore, these initially nongenomic, nonclassical actions seem to serve as additional
interfaces for transcriptional regulation by TH. Aim of this perspective is to summarize the genes that are currently
known to be induced by nonclassical TH action and the mechanisms involved.
TH and gene induction by classical mechanisms
Thyroid hormones (THs) are essential for normal devel-
opment, growth, and metabolism, especially during fetal
development and early childhood. In adults, the primary
effects of THs are manifested by alterations in metabo-
lism, including changes in oxygen consumption, protein,
carbohydrate, lipid, and vitamin metabolism. The pleio-
tropic effects of THs on many different pathways and
target organs become obvious by the clinical features of
hypothyroidism and hyperthyroidism. TH action is
mainly understood as modification of gene expression,
mediated by the nuclear TH receptors (TRs) a and b as
ligand dependent transcription factors. In the classical
model of gene induction by TH, the TRs are located on
thyroid hormone response elements (TREs) in the pro-
moter of target genes, often as homodimers, but also as
heterodimers with the retinoid-X receptor (RXR) [1,2].
In the unliganded state, corepressors are bound to the
TR complex. Upon T3 binding, TR homodimers dissoci-
ate in favor of heterodimer formation. The corepressors
are released and replaced by coactivators. This new
complex ultimately engages the RNA polymerase II in
transcription of the gene (Fig. 1 A).
This model also explains the dominant negative effect
of a mutant TRb on the wildtype TR in the syndrome
of resistance to thyroid hormone (RTH). In RTH,
patients have raised serum TH and raised or inappropri-
ately normal TSH levels. Common clinical features of
RTH include goiter, tachycardia, delayed bone growth
with a variable phenotype [3]. In the majority of cases,
RTH is caused by heterozygous TRb gene mutations.
One mutant TRb as part of a homo- or heterodimer on
a TRE could lead to reduced T3-binding, decreased cor-
epressor release or decreased ability to bind coactivators.
As a consequence, this TRE is blocked by a transcrip-
tionally inactive TRb complex and transcription of its
gene is impaired despite the presence of normal TRb
encoded by the wildtype allele. The mutant TRb thus
confers a dominant negative effect on the wildtype
receptor and consequently inhibits TH action [4]. An
exception to this model is the index family described by
Refetoff et al. with autosomal recessive inheritance [5]
due to a homozygous deletion of the coding region of
the TRb gene [6]. Heterozygous members of this family
were not affected clinically or biochemically, demon-
strating that one wildtype copy of TRb is sufficient for
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normal function. Until now, no mutations in the TRa
gene have been described [2].
Non-classical TH action
In the last ten years, large scale microarray studies have
been performed to determine the effect of TH on gene
expression in animal and human cells [7-12]. In recent
years, it has become evident, that TH can act through
various mechanisms: besides the classical TR/TRE-
mediated mechanism (Fig. 1 A) these are the nonclassi-
cal mechanism of PI3K activation by either liganded
TRb (Fig. 1 B) or the integrin avb3 (Fig. 1 C) as well as
activation of the MAPK cascade via avb3 (Fig. 1 D) (see
below). All these mechanisms potentially influence gene
expression. The initial step of pathway activation by TH
is nongenomic, but the consequences include increased
transcription of certain genes independent of TREs,
which then are nonclassically induced TH target genes.
While microarray studies helped defining gene expres-
sion changes in response to TH, their results represent
a sum effect of both the classical TRE-dependent and
the nonclassical pathway initiated mechanisms of TH
action. It now seems necessary to attribute changes in
gene expression to their underlying mechanisms. In this
overview we aim to summarize which gene induction
could be connected to nonclassical action of TH, espe-
cially in human cells (summarized in table 1).
TRs and PI3K activation
One important nonclassical action of TH is the activa-
tion of PI3K via the liganded TR (Fig. 1 B). T3 had been
shown to be able to activate the PI3K pathway with
downstream phosphorylation and activation of PKB/Akt,
mTOR and p70S6K[13]. This effect of T3 was initially
observed as stimulation of Na,K-ATPase and KCNH2
activity that could be inhibited by the PI3K inhibitors
LY294002 (LY) and wortmannin [14,15]. The crucial
role of the TRb for activation of PI3K became evident
in experiments by Cao et al. in human skin fibroblasts
[13]. Co-immunoprecipitation of both TRb and the reg-
ulatory subunit of PI3K (p85a) demonstrated the asso-
























Figure 1 Mechanisms of gene induction by nonclassical action of TH (modified from [23,36]). A, classical TR/TRE mediated induction of
gene expression; B, activation of PI3K by liganded TRb; C, activation of PI3K via avb3/S1; D, activation of ERK1/2 via avb3/S2
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of TRb and PI3K is independent of T3, as could be
shown in human skin fibroblasts transfected with wild-
type TRb or with the dominant negative mutant TRb
G345R that lacks T3-binding property [13] and with
native TRb in the rat pituitary cell line GH4C1[16]. But
activation of the PI3K/mTOR pathway occurs only after
T3 binding because in cells transfected with the TRb
G345R mutant this pathway was not activated by T3
[11]. Transfection of a dominant negative PI3K p85a
regulatory subunit (Δp85a) expectedly also abrogated
the T3 effect on the kinases downstream of PI3K,
namely Akt, mTOR and p70S6K[13]. Further proof for
PI3K activation by TRb comes from a RTH mutant
TRbPV, which constitutively activates PI3K [17].
Unliganded mutant TRb is still able to bind to p85a
without activating it. The markedly reduced effect of T3
on gene expression in the presence of a mutant TRb in
RTH is probably due to fact that an already reduced
amount of liganded wildtype TRb has to compete with
unliganded mutant wildtype TRb for p85a.
Similar results as for the TRb were obtained for the
TRa. Cao et al. could demonstrate PI3K activation by
T3 mediated by TRa in TRa overexpressing neuronal
cells [18] and Hiroi et al. found TRa1 association with
the p85a subunit of PI3K followed by phosphorylation
of Akt and activation of endothelial nitric oxide synthase
[19].
TH and the integrin avb3 receptor
In 2005, Davis and colleagues identified a structural
plasma membrane protein, the integrin avb3, as a TH
receptor that activated ERK1/2 [20]. Several lines of evi-
dence supported this finding: radiolabeled T4 and T3
could bind to the purified avb3 protein, which was
prevented by antibodies against avb3 as was ERK1/2
activation. SiRNA knockdown of either av or b3 or
both inhibited T4-induced MAPK activation. As several
other integrins, avb3 contains a recognition site for the
peptide sequence Arg-Gly-Asp (RGD). Pretreatment
with an RGD peptide reduced ERK1/2 activation by T4
in the african green monkey fibroblast cell line CV-1.
Tetraiodothyroacetic acid (tetrac), a deaminated T4 deri-
vative, also blocked T4 action through the integrin [20].
Furthermore, effects of T4 were reproduced by T4-agar-
ose, a modified thyroxine that does not cross the cell
membrane [21]. Subsequent studies dissected sites and
mechanisms of avb3 activation and led to the character-
ization of two different TH receptor sites, denoted S1
and S2, with different characteristics and intracellular
consequences [22].
The S1 site of avb3 binds only T3 and is activated at
physiological concentrations. This leads to phosphoryla-
tion and activation of Src and subsequently PI3K (Fig.1
C). T3 action on this site can be blocked by both tetrac
and RGD, as demonstrated in human glioblastoma cells
(U-87 MG): pretreatment with either RGD peptide or
tetrac before addition of T3 abolished Src and PI3K
phosphorylation [23]. Treatment with T3 leads to
nuclear accumulation of TRa in a dose dependent man-
ner. This was not observed after pretreatment with the
PI3K inhibitor LY.
The other TH binding site on integrin avb3, S2, binds
both T4 and, to a lesser extent, T3. TH binding to
avb3/S2 then activates the ERK1/2 pathway (Fig. 1 D).
Both T4 and T3 action can be inhibited by tetrac, but
only T4 action by RGD peptide [23]. Results of TH
binding to the S2 site of avb3 are increased angiogen-
esis [20], proliferation of glioma cells [24] papillary and
Table 1 Gene induction attributed to nonclassical action of TH.











T3 2 nM 24 h [13,9]




T3 2 nM 24 h [28]
HIF-1a b) avb3(S1)/PI3K and avb3(S2)/
ERK1/2
RT-PCR U-87 MG T3 /
T4
1 nM / 100 nM 24 h [23]






T3 2 nM 24 h [28]
GLUT1 TRb/PI3K, target gene of HIF-
1a
microarray/real time PCR primary human skin
fibroblasts
T3 2 nM 24 h [28]
MCT4 TRb/PI3K, target gene of HIF-
1a
microarray/real time PCR primary human skin
fibroblasts
T3 2 nM 24 h [28]
STC-1 TRb/PI3K, target gene of HIF-
1a
microarray/real time PCR primary human skin
fibroblasts
T3 2 nM 24 h [31]
MCL1 TRb/PI3K RT-PCR HK2, HEK293 T3 100 nM, free 6-24h [32]
FGF2 MAPK RT-PCR ECV304 T4 100 nM 6-48 h [33]
free = serumfree medium
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follicular thyroid cancer cells [25] and TRb shuttling
from cytosol to the nucleus [23].
Genes nonclassically induced by TH
ZAKI4a
Activation of PI3K by TRb/T3 and subsequent phos-
phorylation of downstream protein kinases such as Akt
and p70S6K leads to gene induction (Fig. 1 B) and tran-
scriptional regulation by TH via this pathway could be
shown for several genes. ZAKI-4a (also RCAN2 or
DSCR1L1), a calcineurin inhibitor, for example, was
already established as a thyroid hormone target gene in
human primary fibroblasts but no canonical TRE was
found in its promoter [26].
Induction of ZAKI-4a was attributed to the TRb/
PI3K-mechanism of TH action, because the T3 effect on
ZAKI-4a was abrogated by pretreatment with PI3K-
inhibitors wortmannin and LY294002 and transfection
of Δp85a [13]. Additionally, an intact TRb is required
for ZAKI-4a induction. ZAKI-4a induction by T3 was
abrogated after transfection of a dominant negative TRb
mutant (G345R) in human fibroblasts [13]. This was
further supported by a blunted response to T3 in fibro-
blasts from patients with RTH either due to a heterozy-
gous TRb mutation or homozygous TRb deletion
compared to that in normal fibroblasts [9]. Pretreatment
with cycloheximide (CHX) to prevent translation abro-
gated the T3 effect on ZAKI4a mRNA increase, demon-
strating the requirement of prior de novo protein
synthesis. In time course experiments, ZAKI4a mRNA
accumulation in human primary fibroblasts was signifi-
cantly increased only after 6 to 12 hours of T3 treat-
ment [9,26]. ZAKI4a is therefore indirectly induced by
TH and the mediating transcription factor, representing
the immediate link to the PI3K pathway, has yet to be
determined.
HIF-1a
Among the genes found to be induced by T3 in a
microarray study in human primary fibroblasts was
Hypoxia inducible factor (HIF)-1a [9], one subunit of
the basic helix-loop-helix transcription factor HIF-1.
HIF-1 is a key mediator of angiogenesis and metabolic
adaptation to hypoxia in tumors. It is responsible for
elevated expression of glycolytic enzymes and glucose
transporters. The HIF-1b subunit is constitutively
expressed, while HIF-1a is tightly regulated [27]. HIF-
1a synthesis is regulated by both PI3K and MAPK path-
ways, which themselves are activated by receptor tyro-
sine kinases or G-protein-coupled receptors. Ligands for
these include growth factors and hormones such as
growth factors and hormones EGF, IGF-1, insulin and
androgens. T3 treatment in physiological concentrations
was also found to increase HIF-1a mRNA and protein
levels. T3 induced HIF-1a in normal fibroblasts, but not
in fibroblasts from patients with RTH due to a TRb
mutation (A317T), indicating that the TRb is required
for this induction. Pretreatment with the PI3K inhibitor
LY abrogated the T3 effect on both mRNA and protein,
whereas inhibition of the MAPK pathway by PD98059
(PD) had no effect in primary human skin fibroblasts
[28]. These results indicate that HIF-1a induction by T3
is mediated by TRb/PI3K, similar to ZAKI4a. Other
than for ZAKI4a, CHX pretreatment did not prevent
HIF-1a mRNA increase. HIF-1a is therefore directly
induced without the need for prior protein synthesis
[28]. Whether this points to direct induction of HIF-1a
mRNA synthesis or to activation of constitutively
expressed transcription factors needs to be studied.
Lin et al. found HIF-1a to be induced in avb3-expres-
sing human glioblastoma cells after treatment with T3
in physiological concentrations [23]. This effect was
abrogated by pretreatment with LY. From these results
the authors concluded, that T3-induced HIF-1a expres-
sion could be due to PI3K activation via the avb3/S1
site. Yet, specific data supporting that T3/PI3K-mediated
HIF-1a induction is initiated at the integrin TH recep-
tor, such as reduced T3 effect on HIF-1a expression
after pretreatment with tetrac or RGD peptide, were not
provided.
Interestingly, Davis and colleagues also observed a 1.5-
fold HIF-1a mRNA increase after T4 stimulation in U-87
MG cells, an effect that seemed to be inhibited by PD
pretreatment [23], which raises the possibility that HIF-
1a induction could also be mediated by avb3/S2/ERK1/2.
HIF-1 target genes
Besides the a-subunit of the transcription factor HIF-1,
several of its known target genes, harboring hypoxia-
response-elements in their promoter regions, were
induced by TH in the same microarray study: glucose
transporter 1 (GLUT1), phosphofructokinase (PFKP)
and monocarboxylate transporter 4 (MCT4) [9]. Their
products have important roles in cellular glucose meta-
bolism: glucose uptake (GLUT1), glycolysis (PFKP) and
lactate export (MCT4). The response of GLUT1, PFKP
and MCT4 to TH with reproducible mRNA increase
after physiological doses of T3, abrogation of this
response by pretreatment with LY and lack of a signifi-
cant response in cells with a mutant TRb matches the
pattern observed for HIF-1a and expected for HIF-1a
target genes. In addition to the increase in mRNA, for
PFKP an increase could be demonstrated for the protein
by western blot. In contrast to HIF-1a, the induction of
the PFKP, GLUT1 and MCT4 genes was inhibited by
pretreatment with CHX, an inhibitor of protein synth-
esis. This requirement of prior protein synthesis is
expected if their induction is mediated by HIF-1 [28].
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Stanniocalcin (STC)-1 is a polypeptide hormone and
was originally identified as a regulator of calcium/phos-
phate homeostasis in fish and mammals. In humans,
STC1 has been implicated in angiogenesis, apoptosis
and carcinogenesis and, recently, SUMOylation [29].
STC1 was recently characterized as a HIF-1 target gene
as well [30]. STC-1 expression is inducible by T3, an
effect dependent on TRb and prior protein synthesis,
and inhibited by LY and Δp85a. STC-1 therefore also
belongs to this set of genes indirectly induced by TH via
TRb/PI3K and HIF-1 [31].
MCL1
Myeloid cell leukemia (MCL)1 is an anti-apoptotic
member of the B-cell lymphoma 2 (Bcl-2) family of
apoptosis-regulating proteins. A twofold increase in
MCL1 mRNA and protein was observed after treatment
with 100 nM T3 in human kindey-2 (HK2) cells [32]. In
subsequent promoter studies in HEK293 cells trans-
fected with a luciferase reporter vector containing parts
of the MCL1 promoter, treatment with 100 nM T3 in
serumfree medium lead to a twofold increase in MCL1
promoter activity measured by a luciferase assay. In
HEK293 cells, transcription from the MCL1 promoter
also increases twofold in the presence of TRb1, but not
TRa1. Transcriptional activation seems not to be
mediated by a potential TRE-DR4, because it also occurs
in the presence of a disrupted TRE-DR4. This effect was
abolished by inhibiting PI3K with wortmannin. These
results indicate that MCL1 can be induced by T3 and
that activation of PI3K and the TRb1 are required, com-
patible with mechanism B (Fig. 1). From a dose response
curve, T3 appears to have a significant effect on the
MCL1 promoter only with doses of 100 nM and higher.
These concentrations are about 100-fold physiological,
and rather even higher, considering that serumfree med-
ium instead of medium supplemented with T3-depleted
serum was used. This and the fact that the results on
the induction mechanism are from promoter studies
limit conclusions towards the physiological relevance.
FGF2
Finbroblast growth factor (FGF)2 is a member of the
fibroblast growth factor (FGF) family and possesses
angiogenic activities. In ECV304 cells, Davis et al.
observed an increase in FGF2 RNA after stimulation
with 100 nM T4 by RT-PCR [33]. FGF2 cDNA accumu-
lation was significantly increased after 6 h and remained
so for additional 42 hours. Treatment with T3 was not
tested. In the same cells, T4 stimulated FGF2 secretion,
measured by ELISA. This was inhibited by pretreatment
with PD. Interestingly, treatment with 10 nM T3 also
significantly increased FGF2 secretion and its effect was
also inhibited by PD. These results can be interpreted as
pointing to induction of FGF2 by T4 and T3 via the S2
site of the integrin TH receptor followed by MAPK acti-
vation (Fig. 2D), but involvement of both MAPK and
avb3 in FGF2 gene expression still need to be deter-
mined specifically.
Conclusion
TH can act through the TRs a and b on TREs, leading
to gene induction (classical action), or act through TRs/
PI3K in cytoplasm and nucleus or at the cell membrane
on the integrin TH receptor avb3 (nonclassical action).
These nonclassical actions of TH can lead to truly non-
genomic effects, for example activation of the Na+/K
+-ATPase. TH action via avb3 or TR/PI3K can also
induce gene expression, e.g. for the genes describe
above. These actions therefore constitute nonclassically
initiated genomic actions of TH.
Results from most microarray studies so far delivered
the sum of genes induced or repressed by TH without
distinction of the mechanisms involved. For our own
microarray study of T3 induced gene expression in
human fibroblasts [9], we later found several of the
most strongly induced genes after TH treatment to be
downstream of TRb/PI3K. Our interpretation was
that in the PI3K signal transduction pathway the TH
signal can be amplified from kinase to kinase (e.g.
PI3K>AKT>mTOR) before reaching the genomic level.
Amplification of TH action on a TRE seems limited in
comparison.
While it is rather easy to measure TH induced gene
expression, it seems much more complicated to pin
down which of the possible mechanisms of TH action is
responsible for the induction. Studies on nonclassical
TH action often suffer from limitations and attribution
to pathways and receptors is circumstantial. The con-
nection between pathway and gene is not always com-
plete, as for ZAKI the putative transcription factor
linking PI3K and ZAKI4 expression is unknown.
Furthermore, results from cells treated with excessive
T3 concentrations need to be validated with more phy-
siologic concentrations. The requirement of the TH
receptor (TR or avb3) is not always convincingly
shown. Nonclassically induced gene expression by TH
would ideally be demonstrated by direct induction of a
gene with use of physiologic TH concentrations, which
is abrogated by both inhibiting the pathway and the
initial TH receptor suspected to be involved. Ultimately,
the connection of mechanisms of TH actions, sets of
genes and (patho-) physiology is probably much more
intricate than the rather simplistic descriptions here sug-
gest. This is demonstrated by HIF-1a induction, for
which three nonclassical mechanisms of TH action are
possibly responsible (TRb/PI3K, avb3/S1/PI3K and
avb3/S2/ERK1/2).
Moeller and Broecker-Preuss Thyroid Research 2011, 4(Suppl 1):S6
http://www.thyroidresearchjournal.com/content/4/S1/S6
Page 5 of 7
Further studies of these newly described ways through
which TH can modify gene expression may offer new
therapeutic possibilities. The groups of Davis, Mousa
and Hercbergs provided first examples and demon-
strated that tetrac, which inhibits TH action at avb3,
reduces growth of medullary thyroid cancer cells and
renal cancer cells in mouse xenograft models [34,35].
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